Santos-Martínez, SandraAlkhodair, AbdullahNombela-Franco, LuisSaia, FrancescoMuñoz-García, Antonio JGutiérrez, EnriqueRegueiro, AnderJimenez-Diaz, Victor ARivero, FernandoRomaguera, RafaelGómez-Herrero, JavierRodriguez-Gabella, TaniaSathananthan, JanarthananGómez Salvador, ItziarCarrasco-Moraleja, ManuelRodés-Cabau, JosepWebb, JohnLópez, JavierSan Román, J AlbertoAmat-Santos, Ignacio J2023-02-092023-02-092020http://hdl.handle.net/10668/16241This study aimed to evaluate the safety and mid-term efficacy of transcatheter aortic valve replacement (TAVR) in the setting of aortic valve (AV) infective endocarditis (IE) with residual lesion despite successful antibiotic treatment. Patients with AV-IE presenting residual lesion despite successful antibiotic treatment are often rejected for cardiac surgery due to high-risk. The use of TAVR following IE is not recommended. This was a multicenter retrospective study across 10 centers, gathering baseline, in-hospital, and 1-year follow-up characteristics of patients with healed AV-IE treated with TAVR. Matched comparison according to sex, EuroSCORE, chronic kidney disease, left ventricular function, prosthesis type, and valve-in-valve procedure was performed with a cohort of patients free of prior IE treated with TAVR (46 pairs). Among 2,920 patients treated with TAVR, 54 (1.8%) presented with prior AV-IE with residual valvular lesion and healed infection. They had a higher rate of multivalvular disease and greater surgical risk scores. A previous valvular prosthesis was more frequent than a native valve (50% vs. 7.5%; p  TAVR is a safe therapeutic alternative for residual valvular lesion after successfully healed AV-IE. At 1-year follow-up, the risk of IE relapse was low and mortality rate did not differ from TAVR patients free of prior IE, but one-fourth presented with significant aortic regurgitation and >50% required re-admission.enTAVRaortic prosthesishigh surgical riskinfective endocarditisAgedAged, 80 and overAnti-Bacterial AgentsAortic ValveEndocarditis, BacterialFemaleHeart Valve DiseasesHeart Valve ProsthesisHospital MortalityHumansMaleProsthesis-Related InfectionsRecurrenceRegistriesRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTranscatheter Aortic Valve ReplacementTreatment Outcomeresearch article32912458open access10.1016/j.jcin.2020.05.0331876-7605https://doi.org/10.1016/j.jcin.2020.05.033